

ΔΙΑΤΗΡΗΣΗ ΤΗΣ ΟΥΡΟΔΟΧΟΥ ΚΥΣΤΗΣ ΣΕ ΟΥΡΟΘΗΛΙΑΚΟ ΚΑΡΚΙΝΟ

Κορτσιαδης Γ.
Επ. Νοσοκομείο Μεταξά

ΡΥΖΙΚΗ ΚΥΣΤΕΚΤΟΜΗ


Gold standard



- ΣΤΗΝ 5ετια η ΥΠΟΤΡΟΠΗ ΕΛΕΥΘΕΡΗΣ ΝΟΣΟΥ ΕΪΝΑΙ 58%
- ΕΠΙΒΙΩΣΗ ΕΛΕΥΘΕΡΗΣ ΝΟΣΟΥ ΕΪΝΑΙ 66%

**Outcomes of Radical Cystectomy for
Transitional Cell Carcinoma of the Bladder: A
Contemporary Series From the Bladder Cancer Research Consortium**

Shahrokh F. Shariat,* Pierre I. Karakiewicz, Ganesh S. Palapattu, Yair Lotan, Craig G. Rogers,
Gilad E. Amiel, Amnon Vazina, Amit Gupta, Patrick J. Bastian, Arthur I. Sagalowsky,
Mark P. Schoenberg and Seth P. Lerner



Outcomes of Radical Cystectomy for
Transitional Cell Carcinoma of the Bladder: A
Contemporary Series From the Bladder Cancer Research Consortium

Shahrokh F. Shariat,^a Pierre I. Karakiewicz, Ganesh S. Palapattu, Yair Lotan, Craig G. Rogers,
Gilad E. Amiel, Amnon Vazina, Amit Gupta, Patrick J. Bastian, Arthur I. Sagalowsky,
Mark P. Schoenberg and Seth P. Lerner

TUR- BT σε pT2

Table 4. *Survival and bladder preservation*

	5 Yrs	10 Yrs	15 Yrs
Overall (%)	73.7	39.8	24.8
Ca specific (%)	81.9	79.5	76.7
Progression-free with bladder preserved (%)	75.5	64.9	57.8
Local progression-free with bladder preserved (%)	81.8	70.2	61.9

Feasibility of Radical Transurethral Resection as Monotherapy for Selected Patients With Muscle Invasive Bladder Cancer


Eduardo Solsona,* Inmaculada Iborra, Argimiro Collado, José Rubio-Briones, Juan Casanova and Ana Calatrava

From the Services of Urology (ES, II, AC, JRB, JC) and Pathology (AC), Instituto Valenciano de Oncología, Valencia, Spain

TUR- BT σε pT2 με καλά προγνωστικά στοιχεία



- 30% ΠΡΟΟΔΟ ΤΗΣ ΝΟΣΟΥ
- 3% ΜΕ ΜΕΤΑΣΤΑΤΙΚΗ ΝΟΣΟ
- 6% ΜΕΤΑΣΤΑΤΙΚΗ ΝΟΣΟ **ΧΩΡΙΣ ΝΟΣΟ ΣΤΗΝ ΟΥΡΟΔ. ΚΥΣΤΗ**

EBRT



- ΠΛΗΡΗ ΥΦΕΣΗ ΤΗΣ ΝΟΣΟΥ 52% ΑΝ ΔΕΝ ΣΥΝΔΙΑΣΤΕΙ ΜΕ ΧΗΜΕΙΟ
- 64% ΑΝ ΣΥΝΔΙΑΣΤΕΪ ΜΕ ΝΕΟΕΠΙΚΟΥΡΙΚΗ ΧΘ
- ΝΑ ΜΗΝ ΥΠΑΡΧΕΙ IN SITU ΚΑΙ ΔΙΑΤΑΣΗ ΑΠΟ ΑΠΟΦΡΑΞΗ

TMT



TMT


- Μικρομεταστάσεις υπάρχουν στην εξέλιξη της νόσου και αυξάνονται με το στάδιο
- Τα χημειοθεραπευτικά ευαισθητοποιούν καρκινικά κύτταρα στην χθ. (χημειοευαίσθητη νόσος)

Θεραπευτικά σχήματα



A screenshot of the Radiation Therapy Oncology Group (RTOG) website homepage. The header includes the RTOG logo and navigation links such as "HOME", "ABOUT US", "PATIENTS", "CLINICAL TRIALS", "PUBLICATIONS", "CORE LAB", "RESEARCHERS", "RESEARCH ASSOCIATES", and "NEWS". A main banner features a collage of images and the text: "The Radiation Therapy Oncology Group is a recognized leader in working to increase survival and improve the quality of life for cancer patients." Below the banner, there are sections for "RTOG Membership Information & Foundation", "RTOG COOP Bringing RT research to the community", and "news" with a list of recent updates including the addition of Bevacizumab to first-line treatment for glioblastoma and the IDH analysis of the RTOG 0233 study.





Θεραπευτικά σχήματα

Patient characteristics of the two treatment strategies.


	Continuous	Split
Median age (years)	67.25	65
Pts.	1820	1495
Stage [no. Pts (%)]		
T2	778 (43%)	854 (57%)
>T2	652 (36%)	641 (43%)
Unknown	390 (21%)	0 (0%)
Hydronephrosis [no. Pts (%)]		
Yes	213 (12%)	67 (5%)
No	693 (38%)	616 (41%)
Unknown	914 (50%)	912 (54%)
TURB [no. Pts (%)]		
Complete	358 (20%)	60 (4%)
Incomplete	251 (14%)	39 (3%)
Unknown	1211 (66%)	1396 (93%)

A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC)

Giorgio Arcangeli¹, Stefano Arcangeli¹, Lidia Strigari^{2,*}

¹ Laboratory of Medical Physics and Expert Systems, Regina Elena National Cancer Institute, Rome, Italy


² Department of Radiotherapy, Azienda Ospedaliera S. Camillo—Forlanini, Rome, Italy



OS




CR



BIS



SC




LF



CONT

SPLIT

TMT και Μυοδιηθητική νόσος



TMT και Μυοδιηθητική νόσος

OS T2


OS >T2

CR T2



CR > T2

CONT



SPLIT



ΤΜΤ και απόφραξη



CR και OS ΣΕ ΣΥΝΑΡΤΗΣΗ ΜΕ ΤΗΝ ΣΥΝΟΛΙΚΗ ΔΟΣΗ ΤΗΣ ΑΚΤ



ΣΥΜΠΕΡΑΣΜΑΤΑ

- ΣΥΝΕΧΟΜΕΝΗ Η ΔΙΑΚΟΠΤΟΜΕΝΗ ΘΕΡΑΠΕΙΑ ΔΕΝ ΕΠΗΡΕΑΖΕΙ ΤΗΝ ΟΣ ΕΚΤΟΣ ΑΠΌ CR
- ΧΕΙΡΟΤΕΡΑ ΑΠΟΤΕΛΕΣΜΑΤΑ ΣΕ ΠΡΟΧΩΡΗΜΕΝΟ ΣΤΑΔΙΟ ΚΑΙ ΑΠΟΦΡΑΞΗ
-
- ΚΑΛΥΤΕΡΑ ΥΨΗΛΗ ΔΟΣΗ ΑΚΤΙΝΟΒΟΛΙΑΣ 60 Gy
- ΔΕΝ ΥΠΑΡΧΟΥΝ ΣΑΦΗ ΣΥΜΠΕΡΑΣΜΑΤΑ ΓΙΑ ΤΟ ΚΑΛΥΤΕΡΟ ΧΗ/ΚΟ
- ***TMT ΝΑΙ ΑΛΛΑ Ο ΑΣΘΕΝΗΣ ΠΡΕΠΕΙ ΝΑ ΕΛΕΓΧΕΤΑΙ ΓΙΑ ΤΟ ΕΝΔΕΧΟΜΕΝΟ ΚΥΣΤΕΚΤΟΜΗΣ***

ΕΥΧΑΡΙΣΤΩ

